<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02669875</url>
  </required_header>
  <id_info>
    <org_study_id>STOPP</org_study_id>
    <nct_id>NCT02669875</nct_id>
  </id_info>
  <brief_title>Serelaxin To Lower Portal Pressure</brief_title>
  <acronym>STOPP</acronym>
  <official_title>Serelaxin To Lower Portal Pressure in Patients With Cirrhosis and Portal Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>NHS Lothian</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Edinburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Portal hypertension (an increase in blood pressure in the portal vein that carries the blood&#xD;
      from the intestine and spleen to the liver) underlies most of the serious complications of&#xD;
      liver cirrhosis. This randomised placebo controlled study in people with liver cirrhosis&#xD;
      evaluates the acute effects serelaxin (RLX030) infusion on portal hypertension and liver&#xD;
      blood flow.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will investigate the effects of the investigational drug serelaxin (a recombinant&#xD;
      form of the peptide human relaxin-2) on portal hypertension in patients with liver cirrhosis.&#xD;
      The investigators will measure portal pressure by hepatic venous pressure gradient (HVPG) and&#xD;
      hepatic blood flow by indocyanine green (ICG) clearance to evaluate the potential benefits of&#xD;
      the drug. In a recently completed small exploratory open-label phase 2 study (EudraCT no.&#xD;
      201200023626, NCT01640964), Part B demonstrated that serelaxin can lower portal pressure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 18, 2017</start_date>
  <completion_date type="Actual">August 31, 2018</completion_date>
  <primary_completion_date type="Actual">August 31, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in fasting hepatic venous pressure gradient (HVPG)</measure>
    <time_frame>Baseline, after 2 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fasting hepatic venous pressure gradient (HVPG)</measure>
    <time_frame>Baseline, after 1 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fasting hepatic blood flow</measure>
    <time_frame>Baseline, after 2 hours</time_frame>
    <description>Measured from the concentration of indocyanine green (ICG) in the hepatic venous blood vs peripheral venous blood using the Fick Principle</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in inferior vena cava pressure</measure>
    <time_frame>Baseline, after 2 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in cardiac index</measure>
    <time_frame>Baseline, after 2 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in systemic vascular resistance index</measure>
    <time_frame>Baseline, after 2 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>4 weeks</time_frame>
    <description>Adverse events (AE) reporting will be summarized based on number of patients reported with abnormal laboratory values, clinically significant AE, serious adverse events or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in blood biomarker measurements</measure>
    <time_frame>Baseline, after 2 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in aortic pulse wave velocity</measure>
    <time_frame>Baseline, after 2 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Liver Cirrhosis</condition>
  <condition>Hypertension, Portal</condition>
  <arm_group>
    <arm_group_label>Serelaxin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV infusion of serelaxin (RLX030) for 2 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>IV infusion of placebo (20mM sodium acetate pH5) matched to serelaxin for 2 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Serelaxin</intervention_name>
    <description>Serelaxin solution diluted in 5% glucose volume/volume (v/v) solution</description>
    <arm_group_label>Serelaxin</arm_group_label>
    <other_name>RLX030</other_name>
    <other_name>Recombinant human relaxin-2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo solution (20mM sodium acetate pH5) diluted in 5% v/v glucose solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female adult subjects over 18 years of age&#xD;
&#xD;
          2. Able to provide written informed consent and able to understand and willing to comply&#xD;
             with the requirements of the study&#xD;
&#xD;
          3. Clinical imaging-diagnosed or biopsy-proven liver cirrhosis of any aetiology&#xD;
&#xD;
          4. Evidence of portal hypertension either on imaging or previous endoscopy&#xD;
&#xD;
          5. Patients with large/grade 3 varices as identified by endoscopy within 6 months of&#xD;
             screening must be in an endoscopic band ligation programme at the time of study entry&#xD;
&#xD;
          6. Suspected hepatic venous pressure gradient (HVPG) â‰¥10 mmHg at baseline&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy or breast feeding&#xD;
&#xD;
          2. Women of child-bearing potential not using highly effective methods of contraception&#xD;
&#xD;
          3. Severe liver failure defined by one of the following: Prothrombin activity &lt;40%,&#xD;
             Bilirubin &gt;5 mg/dL (85umol/L), hepatic encephalopathy &gt; grade I&#xD;
&#xD;
          4. A history of variceal bleed within 1 month prior to visit 1&#xD;
&#xD;
          5. Presence of any non-controlled and clinically significant disease that could affect&#xD;
             the study outcome or that would place the patient at undue risk&#xD;
&#xD;
          6. Hepatocellular carcinoma or history of malignancy of any organ system (other than&#xD;
             localized basal cell carcinoma of the skin) treated or untreated&#xD;
&#xD;
          7. Portal vein thrombosis&#xD;
&#xD;
          8. Previous surgical shunt or TIPSS&#xD;
&#xD;
          9. Current use of beta-blockers or nitrates, any other drug therapy known to have an&#xD;
             influence on portal pressure (diuretics permitted provided patients have been on a&#xD;
             stable dose for at least 30 days)&#xD;
&#xD;
         10. History of drug or alcohol abuse within 1 month of enrolment&#xD;
&#xD;
         11. Sitting Systolic Blood Pressure &lt;110 mmHg at screening visit or within 10 minutes&#xD;
             prior to starting study drug infusion&#xD;
&#xD;
         12. Use of other investigational drugs within 5 half-lives of enrolment, or within 30&#xD;
             days/until the expected pharmacodynamic effect has returned to baseline, whichever is&#xD;
             longer&#xD;
&#xD;
         13. Significant arrhythmias, which include any of the following: sustained ventricular&#xD;
             tachycardia, bradycardia with sustained ventricular rate &lt; 45 beats per minute or&#xD;
             atrial fibrillation/flutter with sustained ventricular response of &gt; 90 beats per&#xD;
             minute at rest, or Long QT syndrome or corrected QT interval (QTc) &gt; 450 msec (QT&#xD;
             correction will be performed using the Fridericia correction method: QTcF = QT/RR0.33)&#xD;
             for males and &gt; 460 msec for females at screening visit&#xD;
&#xD;
         14. Documented hypersensitivity to intravenous contrast agents and/or iodine&#xD;
&#xD;
         15. Severe renal impairment (eGFR&lt;30mL/min /1.73m2)&#xD;
&#xD;
         16. Significant left ventricular outflow tract obstructions (e.g., severe valvular aortic&#xD;
             stenosis, obstructive cardiomyopathy), severe mitral stenosis, restrictive amyloid&#xD;
             myocardiopathy, acute myocarditis&#xD;
&#xD;
         17. Severe aortic insufficiency or severe mitral regurgitation for which surgical or&#xD;
             percutaneous intervention is indicated&#xD;
&#xD;
         18. Major neurologic event including cerebrovascular events, within 30 days prior to&#xD;
             screening&#xD;
&#xD;
         19. Clinical evidence of acute coronary syndrome currently or within 30 days prior to&#xD;
             enrolment&#xD;
&#xD;
         20. History of hypersensitivity to study drug serelaxin or study drug ingredients&#xD;
&#xD;
         21. Inability to follow instructions or comply with follow-up procedures.&#xD;
&#xD;
         22. Permanent pacemaker, cardiac resynchronisation device or implantable&#xD;
             cardioverter-defibrillator in situ&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Liver Unit, Royal Infirmary of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH164TJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Fallowfield JA, Hayden AL, Snowdon VK, Aucott RL, Stutchfield BM, Mole DJ, Pellicoro A, Gordon-Walker TT, Henke A, Schrader J, Trivedi PJ, Princivalle M, Forbes SJ, Collins JE, Iredale JP. Relaxin modulates human and rat hepatic myofibroblast function and ameliorates portal hypertension in vivo. Hepatology. 2014 Apr;59(4):1492-504. doi: 10.1002/hep.26627. Epub 2014 Mar 3.</citation>
    <PMID>23873655</PMID>
  </reference>
  <reference>
    <citation>Kobalava Z, Villevalde S, Kotovskaya Y, Hinrichsen H, Petersen-Sylla M, Zaehringer A, Pang Y, Rajman I, Canadi J, Dahlke M, Lloyd P, Halabi A. Pharmacokinetics of serelaxin in patients with hepatic impairment: a single-dose, open-label, parallel group study. Br J Clin Pharmacol. 2015 Jun;79(6):937-45. doi: 10.1111/bcp.12572.</citation>
    <PMID>25511105</PMID>
  </reference>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>January 28, 2016</study_first_submitted>
  <study_first_submitted_qc>January 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2016</study_first_posted>
  <last_update_submitted>October 10, 2018</last_update_submitted>
  <last_update_submitted_qc>October 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

